JP6970680B2 - ヒストンデメチラーゼ阻害剤 - Google Patents
ヒストンデメチラーゼ阻害剤 Download PDFInfo
- Publication number
- JP6970680B2 JP6970680B2 JP2018548205A JP2018548205A JP6970680B2 JP 6970680 B2 JP6970680 B2 JP 6970680B2 JP 2018548205 A JP2018548205 A JP 2018548205A JP 2018548205 A JP2018548205 A JP 2018548205A JP 6970680 B2 JP6970680 B2 JP 6970680B2
- Authority
- JP
- Japan
- Prior art keywords
- pyridine
- triazole
- imidazol
- trifluoromethyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *c1c(CC[n]2cnc(-c3nccc(-c4c[n]nn4)c3)c2)cccc1 Chemical compound *c1c(CC[n]2cnc(-c3nccc(-c4c[n]nn4)c3)c2)cccc1 0.000 description 13
- FPBTXNFPADZBHX-UHFFFAOYSA-N C#Cc1cc(-c2c[n](CCc3c(cccc4)c4ccc3)cn2)ncc1 Chemical compound C#Cc1cc(-c2c[n](CCc3c(cccc4)c4ccc3)cn2)ncc1 FPBTXNFPADZBHX-UHFFFAOYSA-N 0.000 description 1
- YBHJDIQTVPGTOQ-UHFFFAOYSA-N C(C(CCC1)c2c1cccc2)[n]1cnc(-c2ncc3nn[nH]c3c2)c1 Chemical compound C(C(CCC1)c2c1cccc2)[n]1cnc(-c2ncc3nn[nH]c3c2)c1 YBHJDIQTVPGTOQ-UHFFFAOYSA-N 0.000 description 1
- JKQLIDDJQPWZHO-UHFFFAOYSA-N C(C1CC1)[n]1cnc(-c(nc2)cc3c2nn[nH]3)c1 Chemical compound C(C1CC1)[n]1cnc(-c(nc2)cc3c2nn[nH]3)c1 JKQLIDDJQPWZHO-UHFFFAOYSA-N 0.000 description 1
- XZZIDGSOPIXHNM-UHFFFAOYSA-N C(C1c(ccc(Oc2ccccc2)c2)c2OCC1)[n]1cnc(-c2ncc3nn[nH]c3c2)c1 Chemical compound C(C1c(ccc(Oc2ccccc2)c2)c2OCC1)[n]1cnc(-c2ncc3nn[nH]c3c2)c1 XZZIDGSOPIXHNM-UHFFFAOYSA-N 0.000 description 1
- ICFJQSMUYFSFQY-UHFFFAOYSA-N C(C1c2cc(Oc3ccccc3)ccc2OCC1)[n]1cnc(-c2ncc3nn[nH]c3c2)c1 Chemical compound C(C1c2cc(Oc3ccccc3)ccc2OCC1)[n]1cnc(-c2ncc3nn[nH]c3c2)c1 ICFJQSMUYFSFQY-UHFFFAOYSA-N 0.000 description 1
- BZDOAFQPLAYILB-UHFFFAOYSA-N C(C1c2ccccc2OCC1)[n]1cnc(-c2ncc3nn[nH]c3c2)c1 Chemical compound C(C1c2ccccc2OCC1)[n]1cnc(-c2ncc3nn[nH]c3c2)c1 BZDOAFQPLAYILB-UHFFFAOYSA-N 0.000 description 1
- XLKANUGVGKJAFP-UHFFFAOYSA-N C(C1c2ccccc2OCC1)[n]1cnc(-c2nccc(-c3c[nH]nn3)c2)c1 Chemical compound C(C1c2ccccc2OCC1)[n]1cnc(-c2nccc(-c3c[nH]nn3)c2)c1 XLKANUGVGKJAFP-UHFFFAOYSA-N 0.000 description 1
- UVNVDHHOAZANLJ-UHFFFAOYSA-N C(CC1)CCN1c(cc1)cnc1-[n]1cnc(-c2ncc3nn[nH]c3c2)c1 Chemical compound C(CC1)CCN1c(cc1)cnc1-[n]1cnc(-c2ncc3nn[nH]c3c2)c1 UVNVDHHOAZANLJ-UHFFFAOYSA-N 0.000 description 1
- LFNSRWQUCCPGBG-UHFFFAOYSA-N CC(C)[Si+](C)c1c(-c2cc(-c3c[n](CCc(cccc4)c4Cl)cn3)ncc2)nn[n]1C Chemical compound CC(C)[Si+](C)c1c(-c2cc(-c3c[n](CCc(cccc4)c4Cl)cn3)ncc2)nn[n]1C LFNSRWQUCCPGBG-UHFFFAOYSA-N 0.000 description 1
- IWKXXMBGUWZVMK-UHFFFAOYSA-N CC(C1=O)=COC=C1O Chemical compound CC(C1=O)=COC=C1O IWKXXMBGUWZVMK-UHFFFAOYSA-N 0.000 description 1
- RKRLQDJTVWZXMM-UHFFFAOYSA-N CC(N1)=NOC1=O Chemical compound CC(N1)=NOC1=O RKRLQDJTVWZXMM-UHFFFAOYSA-N 0.000 description 1
- DAFZHKOUSCNRRF-UHFFFAOYSA-O CC(N[NH2+]C)=NN Chemical compound CC(N[NH2+]C)=NN DAFZHKOUSCNRRF-UHFFFAOYSA-O 0.000 description 1
- LFVXXVDUOZMIPG-UHFFFAOYSA-N CN(c1ccccc1)c1cc(OCCC2C[n]3cnc(-c4ncc5nn[nH]c5c4)c3)c2cc1 Chemical compound CN(c1ccccc1)c1cc(OCCC2C[n]3cnc(-c4ncc5nn[nH]c5c4)c3)c2cc1 LFVXXVDUOZMIPG-UHFFFAOYSA-N 0.000 description 1
- DSDNDTSPUDAUPD-UHFFFAOYSA-N CN(c1ccccc1)c1ccc(C(C[n]2cnc(-c3ncc4nn[nH]c4c3)c2)CCC2)c2c1 Chemical compound CN(c1ccccc1)c1ccc(C(C[n]2cnc(-c3ncc4nn[nH]c4c3)c2)CCC2)c2c1 DSDNDTSPUDAUPD-UHFFFAOYSA-N 0.000 description 1
- BCVZZDCLCPYVLU-UHFFFAOYSA-N CN(c1ccccc1)c1ccc2OCCC(C[n]3cnc(-c4ncc5nn[nH]c5c4)c3)c2c1 Chemical compound CN(c1ccccc1)c1ccc2OCCC(C[n]3cnc(-c4ncc5nn[nH]c5c4)c3)c2c1 BCVZZDCLCPYVLU-UHFFFAOYSA-N 0.000 description 1
- JNNQRMYGNNTCEE-UHFFFAOYSA-N COc(nc1)ccc1-[n]1cnc(-c2ncc3nn[nH]c3c2)c1 Chemical compound COc(nc1)ccc1-[n]1cnc(-c2ncc3nn[nH]c3c2)c1 JNNQRMYGNNTCEE-UHFFFAOYSA-N 0.000 description 1
- JMDIGODBIUTLED-UHFFFAOYSA-N COc1ccc(-[n]2cnc(-c3ncc4nn[nH]c4c3)c2)nc1 Chemical compound COc1ccc(-[n]2cnc(-c3ncc4nn[nH]c4c3)c2)nc1 JMDIGODBIUTLED-UHFFFAOYSA-N 0.000 description 1
- YICFGVAZQJLHKT-UHFFFAOYSA-N C[n]1cnc(-c2ncc3nn[nH]c3c2)c1 Chemical compound C[n]1cnc(-c2ncc3nn[nH]c3c2)c1 YICFGVAZQJLHKT-UHFFFAOYSA-N 0.000 description 1
- LDDOMCLYEPUAEI-UHFFFAOYSA-N C[n]1nnc(-c2cc(-c3c[n](CC4c5ccccc5CCC4)cn3)ncc2)c1 Chemical compound C[n]1nnc(-c2cc(-c3c[n](CC4c5ccccc5CCC4)cn3)ncc2)c1 LDDOMCLYEPUAEI-UHFFFAOYSA-N 0.000 description 1
- QXWKDPPQOJKKFQ-UHFFFAOYSA-N Cc1cc(O)n[s]1 Chemical compound Cc1cc(O)n[s]1 QXWKDPPQOJKKFQ-UHFFFAOYSA-N 0.000 description 1
- YAKLEALDEUYUIJ-UHFFFAOYSA-N Cc1ccc(CCCC2C[n]3cnc(-c4nccc(-c5c(C(F)(F)F)[nH]nn5)c4)c3)c2c1 Chemical compound Cc1ccc(CCCC2C[n]3cnc(-c4nccc(-c5c(C(F)(F)F)[nH]nn5)c4)c3)c2c1 YAKLEALDEUYUIJ-UHFFFAOYSA-N 0.000 description 1
- LAHGPTMNWMCUNX-UHFFFAOYSA-N Cc1n[s]nc1O Chemical compound Cc1n[s]nc1O LAHGPTMNWMCUNX-UHFFFAOYSA-N 0.000 description 1
- QOOHLXDCOHAFJS-UHFFFAOYSA-N FC(c1c(-c2cc(-c3c[n](CCc(c(Cl)ccc4)c4F)cn3)ncc2)nn[nH]1)(F)F Chemical compound FC(c1c(-c2cc(-c3c[n](CCc(c(Cl)ccc4)c4F)cn3)ncc2)nn[nH]1)(F)F QOOHLXDCOHAFJS-UHFFFAOYSA-N 0.000 description 1
- HUYPSMCWEAVAHQ-UHFFFAOYSA-N FC(c1c(-c2cc(-c3c[n](CCc(c(F)cc(F)c4)c4F)cn3)ncc2)nn[nH]1)(F)F Chemical compound FC(c1c(-c2cc(-c3c[n](CCc(c(F)cc(F)c4)c4F)cn3)ncc2)nn[nH]1)(F)F HUYPSMCWEAVAHQ-UHFFFAOYSA-N 0.000 description 1
- JIJUDABPAABLQY-UHFFFAOYSA-N FC(c1c(-c2cc(-c3c[n](CCc(cc4)ccc4F)cn3)ncc2)nn[nH]1)(F)F Chemical compound FC(c1c(-c2cc(-c3c[n](CCc(cc4)ccc4F)cn3)ncc2)nn[nH]1)(F)F JIJUDABPAABLQY-UHFFFAOYSA-N 0.000 description 1
- BBWOOOREENNAAQ-UHFFFAOYSA-N FC(c1c(-c2cc(-c3c[n](CCc4cc(F)ccc4)cn3)ncc2)nn[nH]1)(F)F Chemical compound FC(c1c(-c2cc(-c3c[n](CCc4cc(F)ccc4)cn3)ncc2)nn[nH]1)(F)F BBWOOOREENNAAQ-UHFFFAOYSA-N 0.000 description 1
- GBYIAZVBQUPCIC-UHFFFAOYSA-N Ic1c(-c2cc(-c3c[n](CCc4c(cccc5)c5ccc4)cn3)ncc2)nn[nH]1 Chemical compound Ic1c(-c2cc(-c3c[n](CCc4c(cccc5)c5ccc4)cn3)ncc2)nn[nH]1 GBYIAZVBQUPCIC-UHFFFAOYSA-N 0.000 description 1
- QGUDVVFDWJVNEP-UHFFFAOYSA-N N#Cc1cc(-c(nc[n]2Cc3ccccc3Cl)c2Br)ncc1 Chemical compound N#Cc1cc(-c(nc[n]2Cc3ccccc3Cl)c2Br)ncc1 QGUDVVFDWJVNEP-UHFFFAOYSA-N 0.000 description 1
- VVYJRDFBDSYVHJ-UHFFFAOYSA-N OC(c1cc(-c2c[n](Cc3ccccc3Cl)cn2)ncc1)O Chemical compound OC(c1cc(-c2c[n](Cc3ccccc3Cl)cn2)ncc1)O VVYJRDFBDSYVHJ-UHFFFAOYSA-N 0.000 description 1
- GPGBPBPIEKUSPD-UHFFFAOYSA-N OCc1cc(-c2c[n](Cc3ccccc3Cl)cn2)ncc1 Chemical compound OCc1cc(-c2c[n](Cc3ccccc3Cl)cn2)ncc1 GPGBPBPIEKUSPD-UHFFFAOYSA-N 0.000 description 1
- PTRLBFFSVPFILB-UHFFFAOYSA-N Oc1n[o]c(I)c1 Chemical compound Oc1n[o]c(I)c1 PTRLBFFSVPFILB-UHFFFAOYSA-N 0.000 description 1
- VZEQGRNJPALQFW-UHFFFAOYSA-N c1c(-c2ncc3nn[nH]c3c2)nc[n]1-c(cc1)ncc1Oc1ccccc1 Chemical compound c1c(-c2ncc3nn[nH]c3c2)nc[n]1-c(cc1)ncc1Oc1ccccc1 VZEQGRNJPALQFW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/070,938 US9896436B2 (en) | 2014-09-16 | 2016-03-15 | Histone demethylase inhibitors |
| US15/070,938 | 2016-03-15 | ||
| PCT/US2017/022570 WO2017161033A1 (en) | 2016-03-15 | 2017-03-15 | Histone demethylase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019508447A JP2019508447A (ja) | 2019-03-28 |
| JP2019508447A5 JP2019508447A5 (enExample) | 2020-04-23 |
| JP6970680B2 true JP6970680B2 (ja) | 2021-11-24 |
Family
ID=59852330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018548205A Expired - Fee Related JP6970680B2 (ja) | 2016-03-15 | 2017-03-15 | ヒストンデメチラーゼ阻害剤 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3436445B1 (enExample) |
| JP (1) | JP6970680B2 (enExample) |
| WO (1) | WO2017161033A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CN111406054B (zh) * | 2017-12-05 | 2024-01-02 | 奥莱松基因组股份有限公司 | 作为组蛋白脱乙酰基酶6抑制剂的1,2,4-噁二唑衍生物 |
| CN108957004B (zh) * | 2018-07-09 | 2021-10-19 | 东南大学 | 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用 |
| WO2020245381A1 (en) | 2019-06-06 | 2020-12-10 | Oryzon Genomics, S.A. | 3-(2-(heteroaryl)-pyridin-4-yl)-5-(trifluoromethyl)-1,2,4-oxadiazole derivatives as hdac6 inhibitors |
| CN114805357B (zh) * | 2021-01-21 | 2023-12-19 | 四川大学 | 一种靶向setdb1-ttd的小分子抑制剂及其制药用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101781663B1 (ko) * | 2010-01-13 | 2017-09-25 | 템페로 파마슈티칼즈, 인크. | 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법 |
| WO2014089364A1 (en) * | 2012-12-06 | 2014-06-12 | Quanticel Pharmaceuticals, Inc | Histone demethylase inhibitors |
| US9133166B2 (en) * | 2013-03-14 | 2015-09-15 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| WO2016007722A1 (en) * | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| JP6660060B2 (ja) * | 2014-09-16 | 2020-03-04 | セルジーン クオンティセル リサーチ,インク. | ヒストンデメチラーゼ阻害剤 |
-
2017
- 2017-03-15 WO PCT/US2017/022570 patent/WO2017161033A1/en not_active Ceased
- 2017-03-15 JP JP2018548205A patent/JP6970680B2/ja not_active Expired - Fee Related
- 2017-03-15 EP EP17767465.2A patent/EP3436445B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019508447A (ja) | 2019-03-28 |
| EP3436445A4 (en) | 2019-09-04 |
| WO2017161033A1 (en) | 2017-09-21 |
| EP3436445B1 (en) | 2023-09-06 |
| EP3436445A1 (en) | 2019-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6660060B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| JP6276378B2 (ja) | ヒストンデメチラーゼ阻害剤 | |
| CN106659914B (zh) | 赖氨酸特异性脱甲基酶-1的抑制剂 | |
| EP2928471B1 (en) | Histone demethylase inhibitors | |
| JP6663866B2 (ja) | リジン特異的なデメチラーゼ−1の阻害剤 | |
| EP3436445B1 (en) | Histone demethylase inhibitors | |
| JP2020169183A (ja) | ヒストンデメチラーゼ阻害剤 | |
| US10174003B2 (en) | Histone demethylase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181114 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200310 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200313 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210210 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210301 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210527 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211011 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211029 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6970680 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |